This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Subscribe To Our Newsletter & Stay Updated
